Regenerex, Novartis deal

Regenerex granted Novartis exclusive, worldwide rights and entered a research collaboration deal for Regenerex's hematopoietic stem cell-based Facilitating Cell Therapy (FCRx) technology. The platform is in development to induce stable immunological tolerance in kidney transplant patients to improve graft survival without the need for immunosuppression. Novartis said the technology will also be investigated for use in inherited metabolic storage disorders and hemoglobinopathies. Novartis declined to disclose details, and Regenerex could not be reached. ...